Medimmune Limited

Michael Oberst

Scott A Hammond

Changshou Gao

Melissa Marie Damschroder

Claire Louise Dobson

Ronald Herbst

Godfrey Rainey

Darren Schofield

Stacey Drabic

Srinath Kasturirangan

Michelle Morrow

Yariv Mazor

Brian Lobo

Prakash Manikwar

Jonathan Seaman

Simon Dovedi

Gianluca Carlesso

Kristen Pollizzi

Qun Du

Hui Feng

The disclosure generally provides proteins that bind two epitopes (e.g., a first and a second epitope) and that are bivalent for binding to each of the first and second epitopes. The disclosure also provides for specific binding proteins, including antibodies, which bind to a target protein. The disclosure also provides compositions comprising such proteins, nucleic acid molecules encoding such proteins and methods of making such proteins. The disclosure provides methods of inducing an immune response in a subject as well as methods for treating or preventing cancer in a subject by administering the proteins, nucleic acid molecules and/or compositions to the subject.

Bispecific binding proteins and uses thereof

The disclosure provides humanized anti-OX40 antibodies. Also provided are methods of making such antibodies, and methods of use, e.g., treatment of cancer.

Method of treating cancer with humanized anti-OX40 antibodies

Humanized anti-OX40 antibodies and uses thereof

The disclosure provides OX40L huIgG4 fusion polypeptide subunits comprising a human IgG4 Fc domain, a trimerization domain, and the receptor binding domain of Ox40 ligand, where the fusion polypeptide subunits can self-assemble into hexameric proteins. Also provided are methods of making fusion polypeptide subunits and hexameric proteins, and methods of use, e.g., treatment of cancer.

OX40L fusion proteins and uses thereof

Growing community of inventors

Gaithersburg, MD, United States of America

Michael Oberst